64 results about "Scid mice" patented technology

This invention provides a method for deriving precursors to pluripotent non-embryonic stem (P-PNES) and pluripotent non-embryonic stem (PNES) cell lines. The present invention involves nuclear transfer of genetic material from a somatic cell into an enucleated, zona pellucida free human ooplastoid having a reduced amount of total cytoplasm. The present invention provides a new source for obtaining human and other animal pluripotent stem cells. The source utilizes as starting materials an oocyte and a somatic cell as the starting materials but does not require the use, creation and/or destruction of embryos or fetal tissue and does not in any way involve creating a cloned being. The oocyte never becomes fertilized and never develops into an embryo. Rather, portions of the oocyte cytoplasm are extracted and combined with the nuclear material of individual mature somatic cells in a manner that precludes embryo formation. Murine, bovine, and human examples of the procedure are demonstrated. Subsequently, the newly constructed P-PNES cells are cultured in vitro and give rise to PNES cells and cell colonies. Methods are described for culturing the P-PNES cells to yield purified PNES cells which have the ability to differentiate into cells derived from mesoderm, endoderm, and ectoderm germ layers. Methods are described for maintaining and proliferating PNES cells in culture in an undifferentiated state. Methods and results are described for analysis and validation of pluripotency of PNES cells including cell morphology, cell surface markers, pluripotent tumor development in SCID mouse, karyotyping, immortality in in vitro culture.

Disclosed is a method for expressing hepatitis C virus in an in vivo, animal model. Viable, hepatitis C virus-infected, human hepatocytes are transplanted into a liver parenchyma of a scid/scid mouse host. The scid/scid mouse host is then maintained in a viable state, for up to five days or greater, whereby viable, morphologically intact human hepatocytes persist in the donor tissue and hepatitis C virus is replicated in the persisting human hepatocytes.

A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein <=2x10--9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.

The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×10⁶ human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg/gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg/gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.

The invention discloses three human osteosarcoma cell lines well2, well 5 and LZJ, the collection numbers of the three human osteosarcoma cell lines are CCTCC C200961, CCTCC C200962 and CCTCC C200963 respectively, and the invention further discloses establishment of a corresponding NOD/SCID (nonobese diabetic/severe combined immunodeficiency disease) mouse in-vivo transplantation model, thereby providing a good and stable experimental subject and a model platform for clinical and fundamental research work of osteosarcoma. The established osteosarcoma cell lines can enable the in-vitro stable passage to be more than two years, have stable characters and enable morphology, have immuno-phenotype, chromosome genetics and other characteristics similar to the common osteosarcoma cell lines. The tumorigenesis of NOD/SCID mice is stable, the pathomorphism of tumor bodies is similar to primary tumor tissues of patients, and the animal model is simultaneously sensitive to common chemotherapeutic drugs for the osteosarcoma and can well simulate clinical retracking for clinical patients with the osteosarcoma.

The invention discloses a highly metastatic model of human melanoma, a highly metastatic cell subline of the human melanoma, creation methods for the highly metastatic model and the highly metastatic cell subline, and the dynamic detection of metastasis. The subcutaneously-transplanted mouse highly metastatic model and the corresponding cell subline are established in an in-vivo screening way in a mouse with severe combined immune deficiency (SCID) by using mouse lung metastasis, namely human malignant melanoma cell strain A375 pulmonary metastasis, wherein the highly metastatic cell subline of the human melanoma is A375sci, and has a human tumor cell karyotype; and 60 to 75 hypo-triploid-dominated chromosomes are acrocentric and have a heteroploid karyotype. The cell subline has the two routes of metastasis of blood trails and lymph. The in-vivo screening of the highly-metastatic model is performed by using animals with severe immune deficiency, and is expressed and applied in nude mice. A method for detecting Alu genes by using a polymerase chain reaction (PCR) method is simple, highly sensitive and highly specific, and can be used for detecting organ metastasis, particularly micrometastasis, in a human tumor animal-xenotransplantation model.

The invention relates to an esophageal squamous cell carcinoma primary tumor line CH-H-2 which is used in mammals to produce esophageal squamous cell carcinoma cells. The primary tumor line CH-H-2 can be passed by NOD/SCID mice for multiple times, is significant in solving the inevitable bottleneck problem of distant metastasis in the current esophageal squamous cell carcinoma treatment, and is an ideal object for the basic research and clinical early application of esophageal squamous cell carcinoma.

The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.

The invention relates to phenylbutyryl curcumin derivate and application thereof in anti-tumor drug preparation, in particular to 4-(di(2-chloroethyl) amino) phenylbutyryl curcumin, 4,4'-(di(2-chloroethyl)amino) diphenylbutyryl curcumin, pharmaceutically acceptable salts and a preparation method thereof, and applications of 4-(di(2-chloroethyl) amino) phenylbutyryl curcumin, and 4,4'-(di(2-chloroethyl)amino) di phenylbutyryl curcumin in anti-tumor drug preparation. The phenylbutyryl curcumin derivate can be used for (but not limited to) preparing drugs for treating leukemia, skin cancer, gastric cancer, colon cancer, liver cancer, breast cancer or prostatic cancer. The derivate has obvious inhibition on a plurality of animal tumor cell transplanting modules, especially for the human chronic granulocytic leukemia model constructed by NOD-SCID mice inoculated with the human chronic granulocytic leukemia K562 cell stain, the life prolonging rate is obviously enhanced, and the serious toxicity to mice does not exist.

The invention discloses a building method of a human spongioblastoma cell SCID mouse brain transplantation tumor model. The method comprises the following steps of preparing primary spongioblastoma cells; selecting male SCID mice; dividing the mice into five groups (the first group of mice are inoculated with primary generation spongioblastoma cells in the brain; the second group of mice are inoculated with primary generation spongioblastoma cells in the brain and are infected with HCMV; the third group of mice are inoculated with primary spongioblastoma cells, and are infected with HCMV, andUSP18 high expression adenovirus carriers are used for processing the group; the fourth group of mice are inoculated with primary generation spongioblastoma cells in the brain and are infected with HCMV, interference adenovirus carrier USP18 small interference adenovirus carriers USP18 are used for treating the group of mice; the fifth group of mice is a normal control group); determining a targeted point; performing aseptic inoculation of single-cell suspension; during experiment termination, cutting the head; taking the brain; identifying whether the building of the human spongioblastoma cell SCID mouse brain transplantation tumor model is successful or not. The tumor model can better embody the practical infection state of the HCMV infected human spongioblastoma.

The present invention relates to a method for preparing model of outer marrow infiltration of leukemia-NOD/SCID mice, wherein the method comprises the following steps: 1, preparing a single karyocyte of marrow of leukemia patient, 2. preprocessing the NOD/SCID mice, 3. establishing a model, and 4. identifying the model. The invention firstly adopts a mode of injecting single karyocyte of marrow of leukemia patient through tail-vein injection for establishing the model of outer marrow infiltration of leukemia-NOD/SCID mice. Furthermore the prepared model of outer marrow infiltration of leukemia-NOD/SCID mice has the advantages of high success rate and long survival time. The invention can provide new animal model for researching the outer marrow infiltration mechanism of leukemia, sieving the leukemia medicine, and the targeted therapy of gene and molecule.

The present invention relates to cancer cell system. The establishment of tumor metastasis animal model is essential for the deep research of tumor invasion and metastasis mechanism. SCID mouse is used as experiment target, and the establishment includes subcutaneously inoculating breast cancer parent MCF-7 cell suspension in shoulder of SCID mouse, killing SCID mouse 68 days after inoculation to take out lung for primary culture, cell passage after cells fill the bottom of the culture bottle with the cell being named as LM-MCF-7, subcutaneously re-injecting tumor cell to SCID mouse after 20 generation culture in vivo of LM-MCF-7 and repeating the said steps. The process has tumor forming rate of 100 % and wide metastasis in lung, kidney, spleen, marrow, lymph node, heart, etc. of SCIDmouse is found.

The invention relates to an experimental method for preventing generation and growth of liver cancer by using umbilical cord mesenchymal stem cells. For the first time, an application of the umbilicalcord mesenchymal stem cells to prevent the generation and growth of liver cancer is provided. The UC-MSCs cell preparation method is provided, and the experimental data of the dose of 1*104 cells/treatment course and administration method of the UC-MSCs cells for preventing liver cancer are provided. A UC-MSCs preparation is transplanted firstly, then the liver cancer cells are implanted, and thetumor growth of NOD/SCID mice is observed and compared, the method proves that the umbilical cord mesenchymal stem cells can prevent the generation and development of liver cancer and the dosage of UC-MSCs is provided, the self-renewal and damage repair functions of UC-MSCs in the body's adult organ tissue can be maximized, the body's immunity is improved, and the generation of liver cancer can be prevented, which is beneficial to play a more significant and stable role in later research and clinical applications.

The invention belongs to the field of medicine, and relates to a method for constructing a patient-derived tumor xenograft model in mice immunized with hepatocellular carcinoma based on an organ-likemethod, and an application thereof. The aim of the invention is to use the organ-like culture technology, adopts microcarrier as scaffold material, and combines the liver cancer cells from patient toculture the cells. The invention also discloses an organ-like method for preparing the liver cancer cells-3D material complex, and then directly into that cell-3D material complex is inoculated subcutaneously into normal immunized mice to construct liver cancer transplanted tumor model from patients in vivo, which solved the problems of using nude mice, SCID mice and other immunodeficient mice, which are difficult to feed, expensive and lower tumor formation rate. Especially, it can solve the problem that human hepatocellular carcinoma transplanted tumor model in immunodeficiency mice can notreflect the important role of immune system in tumor occurrence and development, and human tumor transplanted tumor model in immunodeficiency mice has a long tumor formation cycle, which urgently needs the drug-sensitive demand of patients with clinical urgent need. The invention is applied to the field of mouse model construction.

The invention provides a silver nanoparticle composition with lung cancer and prostate cancer resistant activity. The composition contains 20-500mg/kg nano-silver and pharmaceutically acceptable injection excipients (a suspending aid, a dispersing agent, a surfactant, an analgesic, a pH adjustment buffer agent, an osmotic pressure regulator, and water). In the spherical silver nanoparticle powder, the purity of silver is greater than or equal to 99%, and the particle size of silver nanoparticles is 8-75. The experimental result shows that the silver nanoparticle involved in the invention has very strong inhibitory activity on lung cancer H1299 cells and prostate cancer PC-3 cells, and can significantly inhibit H1299 tumor cell transplanted SCID mouse tumor growth in vivo. Therefore, the silver nanoparticle anticancer composition can be used as an antitumor active ingredient individually or in combination for prevention of lung cancer and prevention and treatment of prostate cancer.

This invention disclose a human cancinoma of liver transfer subclone cell system and its set-up method in the following way: a human cancinoma of liver cell HT402 unicell suspension is inoculated into a SCID mouse and the transferred position it determined at lung part and by primary culture and secondary culture, the fetal calf serum concentration in the solution reduces to 10%, cell grows very well thus a cancinoma of liver transfer subclone cell system from parent human cancinoma of liver cell HT402 is set up matched with the parent cell, providing a new experiment material for its study.